Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
FIXX - Homology Medicines, Inc.
Market Cap 75.71M P/E - EPS this Y 63.10% Ern Qtrly Grth -
Income -112.96M Forward P/E -1.13 EPS next Y 2.80% 50D Avg Chg 30.00%
Sales 1.16M PEG 0.14 EPS past 5Y - 200D Avg Chg 5.00%
Dividend N/A Price/Book 0.50 EPS next 5Y -9.40% 52W High Chg -60.00%
Recommedations 3.00 Quick Ratio 7.14 Shares Outstanding 3.23M 52W Low Chg 64.00%
Insider Own 9.29% ROA -36.40% Shares Float 2.04M Beta -0.11
Inst Own 46.76% ROE -90.02% Shares Shorted/Prior 18.82K/17.52K Price 1.31
Gross Margin - Profit Margin - Avg. Volume 331,119 Target Price 1.50
Oper. Margin -7,884.95% Earnings Date May 9 Volume 370,676 Change -8.39%
Healthcare | Biotechnology | United States
About Homology Medicines, Inc.

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Homology Medicines, Inc. News
03/18/24 Homology Medicines Declares Distribution to Common Stockholders
01/03/24 Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
11/16/23 Homology enters reverse merger with Q32 Bio
11/16/23 Q32 Bio and Homology Medicines Announce Merger Agreement
11/14/23 Homology Medicines Reports Third Quarter 2023 Financial Results
10/28/23 Can Homology Medicines (NASDAQ:FIXX) Afford To Invest In Growth?
08/14/23 Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
07/27/23 Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
07/27/23 Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
07/06/23 12 Best Nano Cap Stocks To Buy Now
05/16/23 Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
05/11/23 Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
05/11/23 Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Alloway Paul See Remarks See Remarks Jan 03 Sell 0.566 7,280 4,120 28,036 01/05/24
Michaud Charles Jr See Remarks See Remarks Jan 03 Sell 0.571 1,708 975 11,598 01/05/24
Seymour Albert See Remarks See Remarks Sep 06 Sell 1.15 1,448 1,665 150,874 09/08/23
Jordan Julie Chief Medical Office.. Chief Medical Officer Aug 03 Sell 1.39 1,853 2,576 7,496 08/07/23
Jordan Julie Chief Medical Office.. Chief Medical Officer Aug 03 Option 0 6,579 8,804 08/07/23
Alloway Paul See Remarks See Remarks Mar 02 Sell 1.4467 10,965 15,863 16,706 03/06/23
Smith W Bradford CFO & Treasurer CFO & Treasurer Jan 01 Sell 3.78 2,182 8,248 4,418 01/12/22
Kelly Timothy P Chief Operating Offi.. Chief Operating Officer Jan 01 Sell 3.78 1,406 5,315 2,224 01/12/22
Seymour Albert Chief Scientific Off.. Chief Scientific Officer Jan 01 Sell 3.78 1,661 6,279 131,646 01/12/22
Cohn Gabriel Chief Medical Office.. Chief Medical Officer Jan 01 Sell 3.78 1,661 6,279 2,629 01/12/22
TZIANABOS ARTHUR President & CEO President & CEO Jan 01 Sell 3.78 5,354 20,238 86,011 01/12/22
Smith W Bradford CFO & Treasurer CFO & Treasurer Feb 09 Option 0.64 13,500 8,640 13,500 02/09/21
Kelly Timothy P See Remarks See Remarks Feb 05 Option 6.63 500 3,315 500 02/05/21
Kelly Timothy P See Remarks See Remarks Feb 05 Sell 13 500 6,500 02/05/21
PARMAR KUSH Director Director Dec 28 Sell 12.82 500,000 6,410,000 181,435 12/28/20
PARMAR KUSH Director Director Dec 16 Sell 12.47 500,000 6,235,000 201,435 12/16/20